BTIG Research Reiterates Buy Rating for Waters (WAT)

BTIG Research restated their buy rating on shares of Waters (NYSE:WAT) in a research report report published on Thursday.

Other equities research analysts have also recently issued research reports about the stock. Janney Montgomery Scott reiterated a buy rating and set a $230.00 price objective (up previously from $200.00) on shares of Waters in a research report on Wednesday. Barclays lifted their price objective on shares of Waters from $188.00 to $193.00 and gave the company an equal weight rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Waters from a hold rating to a buy rating and set a $211.00 price objective on the stock in a research report on Monday, October 23rd. William Blair reiterated an outperform rating on shares of Waters in a research report on Tuesday, January 23rd. Finally, Citigroup lifted their price objective on shares of Waters from $190.00 to $223.00 and gave the company a neutral rating in a research report on Wednesday. Twelve analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Waters presently has a consensus rating of Hold and a consensus price target of $203.75.

Shares of Waters (WAT) opened at $218.14 on Thursday. Waters has a one year low of $139.81 and a one year high of $218.72. The company has a market cap of $17,275.37, a P/E ratio of 1,148.17, a price-to-earnings-growth ratio of 2.74 and a beta of 0.82. The company has a current ratio of 2.10, a quick ratio of 5.71 and a debt-to-equity ratio of 0.66.

Waters (NYSE:WAT) last released its earnings results on Tuesday, January 23rd. The medical instruments supplier reported $2.51 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.07. Waters had a net margin of 0.88% and a return on equity of 24.70%. The company had revenue of $687.28 million for the quarter, compared to analysts’ expectations of $671.98 million. During the same quarter last year, the business earned $2.21 EPS. The firm’s revenue was up 9.3% compared to the same quarter last year. equities analysts forecast that Waters will post 8.16 earnings per share for the current year.

In related news, Director Thomas P. Salice sold 3,500 shares of the business’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $200.03, for a total value of $700,105.00. Following the sale, the director now owns 20,349 shares in the company, valued at $4,070,410.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David Terricciano sold 21,997 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $197.52, for a total transaction of $4,344,847.44. Following the completion of the sale, the senior vice president now owns 9,173 shares in the company, valued at approximately $1,811,850.96. The disclosure for this sale can be found here. Insiders sold 108,389 shares of company stock worth $22,239,163 in the last 90 days. 5.07% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Fundsmith LLP increased its position in Waters by 11.7% in the second quarter. Fundsmith LLP now owns 3,833,955 shares of the medical instruments supplier’s stock worth $704,834,000 after purchasing an additional 401,420 shares during the last quarter. Harding Loevner LP increased its position in Waters by 207.1% in the third quarter. Harding Loevner LP now owns 2,768,174 shares of the medical instruments supplier’s stock worth $158,275,000 after purchasing an additional 1,866,848 shares during the last quarter. Janus Henderson Group PLC increased its position in Waters by 1.6% in the third quarter. Janus Henderson Group PLC now owns 1,959,850 shares of the medical instruments supplier’s stock worth $351,832,000 after purchasing an additional 30,057 shares during the last quarter. FMR LLC increased its position in Waters by 7.4% in the second quarter. FMR LLC now owns 1,165,827 shares of the medical instruments supplier’s stock worth $214,326,000 after purchasing an additional 79,824 shares during the last quarter. Finally, Bares Capital Management Inc. increased its position in Waters by 0.6% in the third quarter. Bares Capital Management Inc. now owns 728,948 shares of the medical instruments supplier’s stock worth $130,861,000 after purchasing an additional 4,663 shares during the last quarter. Institutional investors own 92.18% of the company’s stock.

WARNING: This story was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://sportsperspectives.com/2018/01/28/btig-research-reiterates-buy-rating-for-waters-wat.html.

Waters Company Profile

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply